A novel bacterial type III secretion effector, VopV, from the enteric pathogen Vibrio parahaemolyticus has been identified as a key factor in pathogenicity due to its interaction with cytoskeletal actin. One of the repeat units in the long repetitive region of VopV, named VopV rep1 , functions as an actin-binding module. Despite its importance in pathogenesis, the manner in which the effector binds to actin and the subsequent effects on actin dynamics remain unclear. Here, we report the molecular basis of the VopV rep1 /actin interaction. VopV rep1 exists as an unstructured protein in solution but potently and specifically binds filamentous actin (F-actin) and not globular actin (G-actin). The F-actin/VopV rep1 complex was directly visualized at 9.6-Å resolution using electron cryomicroscopy (cryoEM) and helical image reconstitution. The density map revealed the binding site of VopV rep1 at the interface between two actin strands, which is close to the binding site of the bicyclic heptapeptide toxin phalloidin. Consistent with this observation, VopV rep1 alone prevented the depolymerization of F-actin. Overall, VopV rep1 demonstrated unique characteristics in comparison to known actin-binding proteins, but was relatively similar to phalloidin. The phalloidin-like behavior, targeting the interstrand region of actin filaments to stabilize the filament structure, likely contributes to the pathogenicity of V. parahaemolyticus.
1
. The type III secretion system (T3SS), which is the molecular machinery that delivers bacterial effectors into the cytoplasm of infected host cells, is essential for the pathogenicity of this bacterium [2] [3] [4] . Recent reports have shown that one of the type III secretion (T3S) effectors, VopV, plays an important role in the enterotoxicity of V. parahaemolyticus 5, 6 . Among the three repeat units within the long repeat region in VopV, VopV rep1 has been identified as the key unit for F-actin binding and VopV enterotoxicity ( Fig. 1(a) ; UniProt: Q87GF9) 5, 7 .
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The actin cytoskeleton is involved in various cellular processes, and its behavior is strictly controlled by numerous actin-binding proteins and their regulators [8] [9] [10] .To date, a lot of actin-binding proteins have been identified; these proteins affect cellular actin dynamics in various ways, such as sequestering actin monomers, severing or capping the filaments, forming networks or bundles of filaments, and supporting nucleation of filament formation 10 . These different interactions are mediated by individual actin-binding motifs and correspond to the functional diversity of the actin-protein interactions 11, 12 . A number of pathogenic bacteria abuse the versatile ability of actin cytoskeleton to promote its infection 13, 14 . Effectors take control of actin cytoskeleton by directly interacting with the actin molecule as actin-binding proteins or by indirectly interfering with the actin architecture via its regulation system 14, 15 . Despite our increasing knowledge of actin-binding proteins including bacterial effectors, VopV rep1 has no sequence homology with known actin-binding proteins 5 and thus, researchers are not sure how VopV rep1 interacts with actin or how VopV rep1 affects actin dynamics. Here, we analyzed the molecular characteristics of VopV rep1 as a novel actin-binding protein. Direct visualization of the interaction between F-actin and VopV rep1 using electron cryomicroscopy (cryoEM) revealed the unique binding mechanism of VopV rep1 and demonstrated that VopV rep1 had a stabilizing effect on F-actin.
Results
VopV rep1 exists as an unstructured protein in solution, but potently and specifically binds F-actin. First, we overexpressed a construct containing VopV rep1 (residues 361-428) and purified the resulting recombinant protein. The circular dichroism spectrum of VopV rep1 was clearly indicative of a random coil pattern ( Fig. 1(b) ), demonstrating that the recombinant VopV rep1 did not form a stable fold in solution. Indeed, the high proportion of hydrophilic, polar, and glycine residues in VopV rep1 (~67.6%, Fig. 1(a) ) was consistent with the typical characteristics reported for intrinsically unstructured proteins 16 . To assess whether the recombinant protein bound to actin, the binding affinity of VopV rep1 to cytoskeletal actin was determined using isothermal titration calorimetry (ITC). Without a stable fold in solution, VopV rep1 bound to actin with high affinity (K d = 54.4 nM) at a binding stoichiometry of N = 1.06, which is comparable to the well-known F-actin-binding toxin phalloidin 17, 18 , which has a binding affinity of K d = 36.5 nM and a binding stoichiometry of N = 1.16 in our experiment ( Fig. 1(c,d) and Supplementary Table S1 ). These values indicate that their stoichiometries are both 1.0. The affinity of VopV rep1 was as high as or higher than that of other well-studied actin-binding proteins/peptides, such as profilin ( 19 , Wiskott-Aldrich syndrome protein homology domain 2 peptides (K d = 0.052-27 μ M) 20 , and the nebulin repeat fragment (K d = 220 μ M) 21 , suggesting that VopV rep1 was well adapted for actin binding. Because actin exists in a dynamic equilibrium between F-actin and G-actin, we next examined the binding preference of VopV rep1 to each form of actin. An increase in the G-actin/F-actin ratio induced by the F-actin depolymerizing toxin latrunculin 22 caused a decrease in the binding stoichiometry of VopV rep1 to N = 0.28 ( Supplementary Fig. S1 and Table  S1 ), indicating that VopV rep1 preferentially bound F-actin. Conversely, an increase in the F-actin/G-actin ratio using the F-actin-stabilizing toxin phalloidin 18, 23, 24 unexpectedly resulted in complete inhibition of the actin/VopV rep1 interaction ( Fig. 1(c) ). One possible explanation for these observations is that the bindings of phalloidin and VopV rep1 are mutualy exclusive. The observation that VopV rep1 conversely prevented the binding of phalloidin to actin ( Fig. 1(d) ) supported this possibility.
Direct visualization of the VopV rep1 /F-actin interaction by cryoEM. We then used cryoEM image analysis to elucidate the mode of VopV rep1 binding to cytoskeletal F-actin at the molecular level; the unstructured nature of VopV rep1 and the filamentous structure of actin made it nearly impossible to use other approaches, such as single-crystal X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy. Recent advances in the cryoEM method applied to F-actin 25 have enabled the direct visualization of the human cytoskeletal actin/VopV rep1 complex at 9.6-Å resolution ( Fig. 2(a) ). The densities corresponding to the actin molecules were readily assigned to the atomic model of skeletal muscle F-actin without significant conformational change from the previously determined structure ( Fig. 2(a) and Supplementary Fig. S2 ). One apparent exception was observed at the N-terminal region, which oriented in different direction from the model ( Supplementary Fig. S2 ). One possible cause is the difference in sequence between cytoskeletal actin (β -and γ -actins, in this study) and skeletal muscle actin (α -actin, Fujii, et al. 2010) 25 . We should also note that the N-terminal structure of actin is also not observed in recent high resolution studies of F-actin composed of α -actin from striated muscle 26, 27 . In addition to the density of the actin filament, densities corresponding to VopV rep1 were clearly observed along the interface of the two parallel actin strands in a repetitive manner ( Fig. 2(a,b) , colored magenta). One major density (sites a1-a2) was located at the cleft between the two actin strands ( Fig. 2(a,b) ), and an additional density (site b) was found immediately adjacent to the C-terminal region of one actin molecule (actin i + 1; Fig. 2(b,c) ). Therefore, the VopV rep1 densities simultaneously contacted three actin molecules. The major elongated density of sites a1-a2 of VopV rep1 occupied the interface surrounded by the three actin subunits. There is a density extended from the connecting region between densities a1-a2 into the filament interior (named a3 in Fig. 2(b,c) ), which is located deep inside the interstrand cleft. At the a1 site, the density was contacted domains 1 and 2 of an actin i + 1 molecule (Fig. 2(b,c) ). The density extended toward the opposite actin strand, reaching domain 3 of actin i + 2 and further stretched to domain 4 of another actin i molecule running across the longitudinal interface ( Fig. 2(b,c) ). The additional density at site b was located near the C-terminal region at domain 1 of actin i + 1 around the extension of the interface of two actin strands (Fig. 2(b,c) ). Because of the limited resolution of the map, we used the atomic model of actin (PDB ID: 3MFP) 25 to predict the actin residues involved in the interaction with VopV rep1 ( Supplementary Fig. S3 and Table S2 ). The density a3, which is located in the interior of actin filament, is close to the binding site of phalloidin 18, 24 (indicated by asterisk in Fig. 2(b) ). Because the binding stoichiometry was determined by ITC analysis, the densities described above (i.e., sites a1, a2, a3, and b) are likely to correspond to one VopV rep1 molecule. The size of VopV rep1 , 68 residues, was more than sufficient to explain the observed densities, suggesting that some regions connecting the densities were still unstructured and therefore not visible in the map. At a lower threshold, weak densities extending and connecting the major densities are observed ( Supplementary Fig. S4 ). The volume ratio of the extra densities to the actin density is 7.7% and 13.0% at the high and low threshold, respectively. As a coarse estimation, the mass for VopV rep1 includes 29 to 48 residues (calculated from the residue number of actin), meaning that part of 68 residues of VopV rep1 is invisible in this reconstitution due to disorder. This concept was consistent with its natively unstructured properties, as demonstrated in a simulated model (Fig. 2(d) ).
Bound VopV rep1 stabilizes the F-actin protecting from depolymerization. In the density map, VopV rep1 occupied a key position surrounded by three actin monomers that reinforced both the lateral and longitudinal interactions within the filament, suggesting the ability of VopV rep1 to stabilize F-actin. In addition to the observed binding mode, the specific, high-affinity recognition of F-actin results in F-actin stabilization 19 . As expected, the F-actin-stabilizing activity of VopV rep1 was demonstrated by the observation that VopV rep1 strongly protected the actin filament from depolymerization in low-salt conditions (Fig. 3) to the same extent as phalloidin. These results suggested that VopV rep1 played a role in anchoring cytoskeletal actin and simultaneously interfered with actin dynamics by stabilizing F-actin.
Discussion
In this study, a series of biophysical analyses of VopV rep1 revealed its peculiar characteristics as an actin-binding protein. VopV rep1 bound across two actin strands; therefore, the binding likely depended on the higher-order structure of F-actin. Such a binding mode may account for the specificity of F-actin observed in the ITC analysis. In particular, the binding site of VopV rep1 did not include the hydrophobic cleft between domains 1 and 3 of the actin molecule (Fig. 2(c) ), which is recognized by the vast majority of actin-binding proteins 12 . The interstrand region of the actin filament is known to be used as a binding site of the muscle actin-stabilizing factor nebulin 28 and the Salmonella-derived T3S effector SipA
29
. The actin-binding domain of SipA (SipA 446-684 , 238 residues) is significantly larger than VopV rep1 , and the domain itself possesses a stable fold 30 , in contrast to the intrinsically unstructured VopV rep1 . Electron microscope image analysis of the F-actin/SipA 446-684 complex has revealed that the binding site of SipA 446-684 involves a more extended region in addition to the filament interface 29 . Conversely, although the actin-binding fragment of nebulin is relatively small (~35 residues) and intrinsically unstructured in solution 21 , as is VopV rep1 , the affinity of the nebulin fragment to F-actin is significantly weaker than that of VopV rep1 (nebulin, K d = 200-500 μ M vs. VopV rep1 , K d = 54.4 nM) 21 . The actin-binding motif of nebulin (SDxxYK) 21 was not present in the VopV rep1 sequence. Therefore, our data demonstrated that VopV rep1 possessed novel characteristics as an actin-binding protein/peptide, targeting the interstrand interface of F-actin with significantly high affinity through its intrinsic unstructured nature.
F-actin stabilization by VopV rep1 appears to be at least partially responsible for the observed anomaly of cytoskeletal actin in V. parahaemolyticus-infected small intestinal epithelial cells 31 , supported by the observation that the actin cytoskeleton in microvilli, which are the target of V. parahaemolyticus infection, is in dynamic equilibrium 32 and is thus susceptible to perturbation by extrinsic factors. The homeostasis of F-and G-actin is a well-known target for pathogenic effectors 15 . With regard to V. parahaemolyticus, VopL is known to possess F-actin nucleation activity 33, 34 ; thus, VopV and VopL likely facilitate the excessive formation of F-actin in a concerted manner.
VopV rep1 is a small, flexible unit that is a stand-alone module properly tailored for binding and stabilizing F-actin. Full-length VopV contains five homologous VopV rep1 units separated by two other repetitive units ( Fig. 1(a) ) 5 , which simultaneously but individually act on F-actin, resulting in even higher affinity or leading to actin bundling, as observed in VopV-affected cells 5 . Its behavior as an actin-binding unit and the phalloidin-like potency of VopV rep1 suggest that this sequence may have versatile applications in cell biology studies, particular when considering the broad use of phalloidin as an imaging tool to monitor F-actin. In combination with genetic engineering techniques, VopV rep1 could be employed as an inducible factor to target F-actin and cause F-actin stabilization or actin bundling (using a tandem arrangement with an appropriate spacer). Such applications would be useful for the analysis of actin dynamics, F-actin structure 35 , and programmed cell death via F-actin abnormalities in living cells in tissues 36 . Advanced techniques in cryoEM image analysis revealed the interaction of VopV rep1 with F-actin, which is the primary molecular step in the pathogenicity of V. parahaemolyticus. Unexpectedly, VopV was found to target a similar site as phalloidin and demonstrated a unique binding mode for F-actin that differed from that of known actin-binding proteins. The unstructured nature of VopV rep1 may contribute to its ability to enter the elongated binding site at the interstrand region of F-actin while maintaining its affinity and specificity. This novel and well-organized binding mode for VopV rep1 provides a glimpse into the unusual association between the pathogenic effector of V. parahaemolyticus and the fundamental human cytoskeleton.
Methods
For details of the MD calculation for making simulated model of VopV rep1 see Supplemental Methods.
Overexpression and purification of VopV rep1 . The VopV rep1 sequence was subcloned into a pET32b vector (Novagen) containing a modified multiple cloning site to express a fusion protein composed of thioredoxin, His 6 , and a thrombin protease site followed by VopV rep1 . BL21(DE3) cells (Novagen) were transformed with this vector and cultivated in LB medium supplemented with 100 mg/mL ampicillin at 37 °C. Protein expression was induced with 0.2 mM IPTG, and cells were further incubated at 20 °C for 6 h. The cells were harvested by centrifugation, flash frozen in liquid N 2 , and thawed on ice. The cells were then resuspended in lysis buffer (20 mM Tris-HCl, pH 7.5, and 500 mM NaCl), treated with 0.2% Triton X-100 for 20 min on ice, and disrupted by ultrasonication. The cell debris was then removed by centrifugation. The supernatant was applied to a Ni-charged HiTrap Chelating column (GE Healthcare) equilibrated with lysis buffer. The target protein was eluted with lysis buffer containing 300 mM imidazole. The fusion tags were removed through thrombin cleavage (Sigma-Aldrich) for 18 h at 25 °C during dialysis in Tris-HCl (pH 7.5) and 5 mM NaCl. The VopV rep1 protein was further applied to a HiTrap SP column (GE Healthcare) and eluted using a 5-300 mM NaCl gradient. After concentration using an Amicon ultra concentrator (Millipore), VopV rep1 was further purified by size-exclusion chromatography using a HiLoad 26/60 Superdex 75 prep grade column (GE Healthcare). The purity was verified using SDS-PAGE analysis. Purified VopV rep1 was stored at -80 °C prior to use. Circular dichroism (CD) spectroscopy. VopV rep1 was dialyzed in 20 mM Tris-HCl (pH 7.2). The CD spectrum of 125 μ M VopV rep1 was acquired using a JASCO J-720 spectropolarimeter in a 1-mm quartz cell at 20 °C.
Isothermal titration calorimetry (ITC). VopV rep1 and cytoskeletal actin were dialyzed in 30 mM
Tris-HCl (pH 7.5) and 75 mM KCl. The titration experiment was conducted using a MicroCal iTC200 calorimeter. The measurement was performed in general actin buffer (20 mM Tris-HCl, pH 7.5, 50 mM KCl, 1 mM MgCl 2 , and 0.2 mM ATP) at 25 °C. It was assumed that almost all the actin molecules formed F-actin in this solution. Phalloidin was dissolved in DMSO and used at a concentration of 110 μ M in general actin buffer containing 1% DMSO. The sample cell was filled with 8.8 μ M actin, and 110 μ M VopV rep1 or phalloidin was loaded in the titration syringe. To account for the diluted DMSO in the case of its use as a drug, 1% DMSO was added to the actin solution. An inhibition assay was performed using a sequential titration experiment in which the actin solution that was titrated by the first binding sample, that is, VopV rep1 or phalloidin, was used for the second titration assay with phalloidin or VopV rep1 , respectively. The obtained data were analyzed using Origin 7 Software (OriginLab Corporation) and fitted using a one-site binding model.
CryoEM.
Image collection. The F-actin/VopV rep1 sample retrieved after ITC titration (12.5 μ M VopV rep1 , 7.8 μ M actin) was used for cryoEM image data collection and analysis. The experimental procedures for cryoEM were identical to those of a previously published report 25 . Briefly, the sample solution was loaded on Quantifoil holey carbon molybdenum grid (R0.6/1.0, Quantifoil) and plunge-frozen into liquid ethane using Vitrobot (FEI). Image collection was performed at temperature of 50-60 K using a JEOL JEM3200FSC electron microscope equipped with a liquid helium-cooled specimen stage, an Ω -type energy filter, and a field-emission electron gun operated at 200 kV. In total, 445 images were recorded on a CCD camera (TemCam-F415MP, TVIPS) at magnification of around 170,100× and a defocus range of 1.0-2.4 μ m. The image pixel size corresponded to 1.677 Å.
Image analysis. Image analysis using the iterative helical real-space reconstitution method (IHRSR) 37 was performed using EMAN 1.93 38 and SPIDER 15.06 39 . The defocus and astigmatism of each image were determined using CTFFIND 40 . In total, 39,910 image segments of F-actin were boxed, and ~121,000 actin molecules were included. Images were corrected for phase and amplitude contrast transfer function (CTF). The images were aligned and cross-correlated to a series of reference projection images, and a 3D image was reconstituted by back projection. The 3D images were improved by imposing helical symmetry parameters in an iterative manner and refined until convergence.
Model analysis. The rabbit α -skeletal actin structure (PDB ID: 3MFP) was fitted to the density, and symmetrical actin units were generated using UCSF Chimera software 41 . In the iterative process of image analysis, the helical symmetry and axial repeat distance were refined and converged to a subunit rotation of -166.8° and an axial repeat of 27.6 Å, which resulted in a helical symmetry of approximately 41 subunits/19 turns (~2.158). This value of the F-actin/VopV rep1 complex corresponded to a helical structure slightly overtwisted from that of native F-actin, which was reported in a study of rabbit skeletal muscle actin with approximately 67 subunits/31 turns (~2.161) 25 and was relatively close to the phalloidin-bound form of F-actin with approximately 69 subunits/32 turns (~2.156) 18 . F-actin stabilization assay. F-actin stabilization was performed using the Actin Binding Protein Biochem Kit (Cytoskeleton Inc.). Briefly, F-actin was pre-assembled from purified human platelet nonmuscle actin (1 mg/mL) at room temperature for 1 h in F-buffer containing 0.2 mM CaCl 2 , 50 mM KCl, 2 mM MgCl 2 , and 1 mM ATP in 5 mM Tris-HCl (pH 8.0). The assembled F-actin was then depolymerized by a 1:5 dilution with G-buffer (0.2 mM CaCl 2 in 5 mM Tris-HCl, pH 8.0) in the absence or presence of VopV rep1 , latrunculin, and phalloidin under the indicated final concentrations. After 0, 2, or 4 h of incubation on ice, the samples were ultracentrifuged (120,000 × g for 2 h) at 4 °C. The pellets were analyzed using SDS-PAGE, and the gels were stained with Coomassie blue. The density of the pelleted F-actin in individual fractions was determined using ImageJ software (National Institutes of Health).
